Galidesivir

BioCryst to Report Third Quarter 2022 Financial Results on November 1

Retrieved on: 
Tuesday, October 18, 2022

RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will report its third quarter 2022 financial results Tuesday, November 1, 2022.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will report its third quarter 2022 financial results Tuesday, November 1, 2022.
  • BioCryst management will host a conference call and webcast at 8:30 a.m.
  • ET that day to discuss the financial results and provide a corporate update.
  • The live call may be accessed by dialing 866-374-5140 for domestic callers and 404-400-0571 for international callers and using conference ID 28663801#.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, October 4, 2022

The options and RSUs were granted as of September 30, 2022 as inducements material to each employee entering into employment with BioCryst.

Key Points: 
  • The options and RSUs were granted as of September 30, 2022 as inducements material to each employee entering into employment with BioCryst.
  • The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options and RSUs are subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
  • RAPIVAB (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing.

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

Retrieved on: 
Wednesday, September 14, 2022

RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the companys significant pipeline of development candidates.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the companys significant pipeline of development candidates.
  • Dr. Ryan Arnold has been appointed as the companys new chief medical officer.
  • Dr. Arnold joins Dr. Sheridan and Dr. Helen Thackray, the companys chief research and development officer, as physicians on the companys leadership team.
  • Dr. Sheridan joined BioCryst from Amgen in July 2008 as chief medical officer.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, September 6, 2022

The options and RSUs were granted as of August 31, 2022 as inducements material to each employee entering into employment with BioCryst.

Key Points: 
  • The options and RSUs were granted as of August 31, 2022 as inducements material to each employee entering into employment with BioCryst.
  • The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options and RSUs are subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
  • RAPIVAB (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing.

BioCryst to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, August 31, 2022

RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 11:35 a.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 11:35 a.m.
  • ET and the H.C. Wainwright 24th Annual Global Investment Conference.
  • A pre-recorded fireside chat for the H.C. Wainwright conference will be made available Monday, September 12, 2022, at 7:00 a.m.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.

FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

Retrieved on: 
Wednesday, August 31, 2022

RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for BCX9250 for the treatment of fibrodysplasia ossificans progressiva (FOP).

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for BCX9250 for the treatment of fibrodysplasia ossificans progressiva (FOP).
  • We appreciate the FDAs decision to grant orphan drug designation to BCX9250 as we work toward our goal of bringing this important oral investigational therapy to FOP patients.
  • Earlier this year, BioCryst announced that BCX9250 has received Fast Track designation from the FDA, in addition to orphan drug designation and PRIME designation from the European Medicines Agency (EMA).
  • This press release contains forward-looking statements, including statements regarding BioCrysts plans and expectations for BCX9250 and the potential benefits associated with an FDA orphan drug designation.

BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients

Retrieved on: 
Friday, August 26, 2022

The data, which are the first data with BCX9930 in patients with C3G, are being presented in a poster session at the 18th European Meeting on Complement in Human Disease, which is being held in Bern, Switzerland, from August 26-29, 2022.

Key Points: 
  • The data, which are the first data with BCX9930 in patients with C3G, are being presented in a poster session at the 18th European Meeting on Complement in Human Disease, which is being held in Bern, Switzerland, from August 26-29, 2022.
  • The analyses found that a single oral dose (600 mg) of BCX9930:
    Demonstrated >99 percent (median) suppression of the AP, and that >98 percent (median) suppression was maintained for 24 hours post-dosing, in C3G patients.
  • Achieved rapid (within two hours) and maximal (median >99 percent relative to pre-dose levels) suppression of the generation of C3a, a product of C3 convertase activity, in both healthy volunteers and C3G patients.
  • Currently, BioCryst is conducting the RENEW proof-of-concept basket study evaluating BCX9930 in C3G, immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN), all rare renal diseases caused by dysregulation of the alternative pathway.

BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones

Retrieved on: 
Thursday, August 4, 2022

RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.
  • In the second quarter, more new physicians prescribed ORLADEYO than any quarter since the third quarter of 2021.
  • Selling, general and administrative expenses for the second quarter of 2022 increased to $38.0 million, compared to $26.3 million in the second quarter of 2021 (+44 percent y-o-y).
  • Interest expense was $24.0 million in the second quarter of 2022, compared to $13.5 million in the second quarter of 2021 (+78 percent y-o-y).

BioCryst Resumes Enrollment in BCX9930 Clinical Program

Retrieved on: 
Thursday, August 4, 2022

The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930.

Key Points: 
  • The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930.
  • On April 8, 2022, BioCryst announced that the company had voluntarily paused enrollment in BCX9930 clinical trials while it investigated observed elevations in serum creatinine (SCr) seen in some patients at the 500 mg twice daily dose.
  • All patients will receive BCX9930 in part 2 (weeks 25-52) to assess the long-term safety, tolerability and effectiveness of BCX9930.
  • ET today to discuss its second quarter financial results and provide a corporate update, including updates on the BCX9930 clinical program.

BioCryst to Report Second Quarter 2022 Financial Results on August 4

Retrieved on: 
Thursday, July 21, 2022

RESEARCH TRIANGLE PARK, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2022 financial results Thursday, August 4, 2022.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2022 financial results Thursday, August 4, 2022.
  • BioCryst management will host a conference call and webcast at 8:30 a.m.
  • ET that day to discuss the financial results and provide a corporate update.
  • The live call may be accessed by dialing 866-374-5140 for domestic callers and 404-400-0571 for international callers and using conference ID 68509725#.